Ercelep Özlem, Tataroğlu Deniz, Özçelik Melike, Sürmeli Heves, Değirmenci Mustafa, İnanç Mevlüde, Aliustaoğlu Mehmet, Gümüş Mahmut
Kartal Dr. Lütfi Kırdar Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey.
University of Health Sciences Turkey, Tepecik Training and Research Hospital, Clinic of Medical Oncology, İzmir, Turkey.
Turk J Obstet Gynecol. 2020 Jun;17(2):123-127. doi: 10.4274/tjod.galenos.2020.90699. Epub 2020 Jul 29.
To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer.
Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated.
The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months. All 64 patients received a median of 6 (range, 1-12) bevacizumab and 6 (range, 2-12) chemotherapy cycles. The chemotherapy regimens used with bevacizumab were cisplatin and paclitaxel in 31 (48%) and carboplatin and paclitaxel in 33 (52%) patients. The survival in patients treated with bevacizumab and cisplatin plus paclitaxel was better-particularly in patients with no previous cisplatin-based radiosensitizer therapy-than those treated with carboplatin, paclitaxel, and bevacizumab (p=0.023). The bevacizumab dose was 7.5 mg/kg in 30 patients (47%) and 15 mg/kg in 34 patients (53%) every 21 days. No significant difference was reported in the OS and the PFS between the two groups. While the most common all-grades adverse events were nausea, neutropenia, anemia, and peripheral sensory neuropathy, the most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy.
Adding bevacizumab to platinum and paclitaxel chemotherapy in a case of metastatic or recurrent cervical cancer is an effective and tolerable treatment for Turkish patients.
评估贝伐单抗（一种抗血管内皮生长因子单克隆抗体）联合细胞毒性化疗方案对土耳其复发性和转移性宫颈癌患者的疗效。
回顾性评估了2013年至2017年间64例接受贝伐单抗联合一线顺铂或卡铂及紫杉醇化疗的转移性或复发性宫颈癌患者的数据。
患者的平均年龄为49岁（范围28 - 68岁），中位随访时间为12个月（范围2 - 53个月），中位无进展生存期（PFS）为8个月，中位总生存期（OS）为23个月。所有64例患者接受贝伐单抗的中位疗程为6个（范围1 - 12个），化疗中位疗程为6个（范围2 - 12个）。与贝伐单抗联合使用的化疗方案中，31例（48%）患者使用顺铂和紫杉醇，33例（52%）患者使用卡铂和紫杉醇。接受贝伐单抗联合顺铂加紫杉醇治疗的患者生存率更高，尤其是那些之前未接受过基于顺铂的放射增敏治疗的患者，优于接受卡铂、紫杉醇和贝伐单抗治疗的患者（p = 0.023）。30例患者（47%）的贝伐单抗剂量为7.5 mg/kg，34例患者（53%）为15 mg/kg，每21天给药一次。两组的总生存期和无进展生存期无显著差异。最常见的所有级别不良事件为恶心、中性粒细胞减少、贫血和周围感觉神经病变，最常见的≥3级不良事件为中性粒细胞减少、贫血和周围感觉神经病变。
对于土耳其转移性或复发性宫颈癌患者，在铂类和紫杉醇化疗中添加贝伐单抗是一种有效且耐受性良好的治疗方法。
